COX2 inhibitors or PGE2 receptors EP2 and EP4 antagonists combined with anti-PD-1 blockade have shown the therapeutic potential in improving eradication of tumors and augmenting the numbers of functional tumor-specific cytotoxic T lymphocytes (CTL) function in tumor-bearing hosts (Miao et al., 2017). Here, PTGS2 is linked to neoplasm.